Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
Completed Alterity protocol ATH434-201. [+1]
Discontinued prior ATH434 treatment (ATH434-201) for any reason. [+1]